Sino Biopharmaceutic (SBMFF) 0.6400 $SBMFF WuXi
Post# of 273254
Posted On: 09/23/2016 7:16:40 AM
Sino Biopharmaceutic (SBMFF) 0.6400 $SBMFF
WuXi AppTec Congratulates Chia Tai Tianqing Pharmaceutical Group and Janssen for Licensing Agreement
PR Newswire - Fri Jan 08, 7:00AM CST
WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, today congratulated Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ), a well-established Chinese pharmaceutical company that is a subsidiary of Sino Biopharmaceutical Ltd., and Janssen Pharmaceuticals Inc. (Janssen), a leading global pharmaceutical company, for having reached an exclusive license agreement. Under this agreement, CTTQ grants Janssen rights to develop and commercialize an undisclosed immuno-modulating agent to treat chronic hepatitis B virus (HBV) infection globally outside China. Both CTTQ and Janssen are long-time collaboration partners of WuXi. In 2013, CTTQ signed a contract with WuXi to discover anti-HBV small-molecule drugs. WuXi provided end-to-end integrated research services on the compound that is the subject of this license agreement.
LifeBond Closes $27 Million Series D Financing Round
PR Newswire - Wed Aug 05, 6:15AM CDT
LifeBond, a leader in the development of bio-surgical medical devices for tissue repair, announced today it has closed a $27M Series D preferred equity investment. Participants in the round include Pitango Venture Capital, Adams Street Partners, Sino Biopharmaceutical Ltd., and all existing investors.
Medullary Thyroid Cancer - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ldtm6m/medullary_thyroid) has announced the addition of the "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" report to their offering. "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" provides data on the Medullary Thyroid Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Medullary Thyroid Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Medullary Thyroid Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Medullary Thyroid Cancer Therapeutics Clinical Trials - AstraZeneca PLC - Exelixis, Inc. - Eisai Co., Ltd. - Sino Biopharmaceutical Limited - Sanofi - Immunomedics, Inc. - Globeimmune, Inc. - EANM Research Ltd. - Bayer AG - Amgen Inc. - National Cancer Institute - University of Kentucky - University of Wisconsin Madison - Garden State Cancer Center - University of Texas M. D. Anderson Cancer Center - University of Southern California - Sidney Kimmel Comprehensive Cancer Center - University of Washington - Medical University of Vienna - Leiden University Medical Center For more information visit http://www.researchandmarkets.com/research/ld...ry_thyroid
IMMU: 3.30 (unch), AZN: 34.28 (+0.53), AMGN: 175.62 (+1.77), EXEL: 14.74 (unch)
Medullary Thyroid Cancer Therapeutics Clinical Trials Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Thu Apr 30, 6:31AM CDT
The report "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" provides elemental information and data relating to the clinical trials on Medullary Thyroid Cancer. Complete report on H1 2015 Clinical Trials review of "Medullary Thyroid Cancer" addiction with 44 market data tables and 109 figures, spread across 65 pages is available at http://www.rnrmarketresearch.com/medullary-th...eport.html .
IMMU: 3.30 (unch), EXEL: 14.74 (unch)
WuXi AppTec Congratulates Chia Tai Tianqing Pharmaceutical Group and Janssen for Licensing Agreement
PR Newswire - Fri Jan 08, 7:00AM CST
WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, today congratulated Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ), a well-established Chinese pharmaceutical company that is a subsidiary of Sino Biopharmaceutical Ltd., and Janssen Pharmaceuticals Inc. (Janssen), a leading global pharmaceutical company, for having reached an exclusive license agreement. Under this agreement, CTTQ grants Janssen rights to develop and commercialize an undisclosed immuno-modulating agent to treat chronic hepatitis B virus (HBV) infection globally outside China. Both CTTQ and Janssen are long-time collaboration partners of WuXi. In 2013, CTTQ signed a contract with WuXi to discover anti-HBV small-molecule drugs. WuXi provided end-to-end integrated research services on the compound that is the subject of this license agreement.
LifeBond Closes $27 Million Series D Financing Round
PR Newswire - Wed Aug 05, 6:15AM CDT
LifeBond, a leader in the development of bio-surgical medical devices for tissue repair, announced today it has closed a $27M Series D preferred equity investment. Participants in the round include Pitango Venture Capital, Adams Street Partners, Sino Biopharmaceutical Ltd., and all existing investors.
Medullary Thyroid Cancer - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ldtm6m/medullary_thyroid) has announced the addition of the "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" report to their offering. "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" provides data on the Medullary Thyroid Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Medullary Thyroid Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Medullary Thyroid Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Medullary Thyroid Cancer Therapeutics Clinical Trials - AstraZeneca PLC - Exelixis, Inc. - Eisai Co., Ltd. - Sino Biopharmaceutical Limited - Sanofi - Immunomedics, Inc. - Globeimmune, Inc. - EANM Research Ltd. - Bayer AG - Amgen Inc. - National Cancer Institute - University of Kentucky - University of Wisconsin Madison - Garden State Cancer Center - University of Texas M. D. Anderson Cancer Center - University of Southern California - Sidney Kimmel Comprehensive Cancer Center - University of Washington - Medical University of Vienna - Leiden University Medical Center For more information visit http://www.researchandmarkets.com/research/ld...ry_thyroid
IMMU: 3.30 (unch), AZN: 34.28 (+0.53), AMGN: 175.62 (+1.77), EXEL: 14.74 (unch)
Medullary Thyroid Cancer Therapeutics Clinical Trials Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Thu Apr 30, 6:31AM CDT
The report "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" provides elemental information and data relating to the clinical trials on Medullary Thyroid Cancer. Complete report on H1 2015 Clinical Trials review of "Medullary Thyroid Cancer" addiction with 44 market data tables and 109 figures, spread across 65 pages is available at http://www.rnrmarketresearch.com/medullary-th...eport.html .
IMMU: 3.30 (unch), EXEL: 14.74 (unch)
(0)
(0)Scroll down for more posts ▼